84.68
price up icon0.26%   0.15
 
loading
Astrazeneca PLC stock is traded at $84.68, with a volume of 4.47M. It is up +0.26% in the last 24 hours and up +6.53% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$84.53
Open:
$84.35
24h Volume:
4.47M
Relative Volume:
0.92
Market Cap:
$262.55B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
31.81
EPS:
2.6622
Net Cash Flow:
$8.49B
1W Performance:
-0.86%
1M Performance:
+6.53%
6M Performance:
+27.85%
1Y Performance:
+9.57%
1-Day Range:
Value
$84.05
$84.92
1-Week Range:
Value
$83.84
$86.48
52-Week Range:
Value
$61.24
$86.57

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
84.66 262.09B 56.53B 8.32B 8.49B 2.6622

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
10:42 AM

Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener

10:42 AM
pulisher
08:11 AM

Will AstraZeneca PLC Depositary Receipt bounce back from current supportJuly 2025 Earnings & Real-Time Sentiment Analysis - newser.com

08:11 AM
pulisher
08:08 AM

Will breakout in AstraZeneca PLC Depositary Receipt lead to full recoveryJuly 2025 Big Picture & Reliable Entry Point Trade Alerts - newser.com

08:08 AM
pulisher
07:59 AM

Advanced analytics toolkit walkthrough for AstraZeneca PLC Depositary ReceiptJuly 2025 Pullbacks & Low Drawdown Investment Strategies - newser.com

07:59 AM
pulisher
07:54 AM

AstraZeneca (AZN) Agrees to Lower Drug Prices in the U.S. with S - GuruFocus

07:54 AM
pulisher
07:48 AM

AstraZeneca's drug pricing deal with Trump far from clear result, say analysts - Proactive financial news

07:48 AM
pulisher
05:44 AM

Why AstraZeneca PLC Depositary Receipt stock remains undervaluedJuly 2025 Breakouts & Daily Technical Stock Forecast Reports - newser.com

05:44 AM
pulisher
05:30 AM

AstraZeneca: Drug Pricing Agreement Mitigates Threats of Tariffs and Price Controls - Morningstar Canada

05:30 AM
pulisher
05:13 AM

Vanguard Personalized Indexing Management LLC Increases Stock Holdings in AstraZeneca PLC $AZN - MarketBeat

05:13 AM
pulisher
05:08 AM

Is AstraZeneca PLC Depositary Receipt stock ready for a breakoutWeekly Risk Summary & Weekly High Potential Stock Alerts - newser.com

05:08 AM
pulisher
05:05 AM

Trending tickers: TSMC, AstraZeneca, Lloyds, Fresnillo and Canal+ - Yahoo

05:05 AM
pulisher
04:36 AM

AstraZeneca confirms deal with US government on drug prices - MarketScreener

04:36 AM
pulisher
04:09 AM

How to monitor AstraZeneca PLC Depositary Receipt with trend dashboardsMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com

04:09 AM
pulisher
03:42 AM

AstraZeneca reaches agreement with Trump to lower its prices in the US - MarketScreener

03:42 AM
pulisher
02:38 AM

AstraZeneca agrees to offer US discounts in exchange for no tariffs - Proactive Investors

02:38 AM
pulisher
02:33 AM

AstraZeneca to cut US drug prices in key White House deal - Sharecast.com

02:33 AM
pulisher
02:11 AM

AstraZeneca : Agreement with US Govt to lower medicine prices - MarketScreener

02:11 AM
pulisher
02:10 AM

Trump announces deal with AstraZeneca on drug prices, tariffs - MarketScreener

02:10 AM
pulisher
02:08 AM

AstraZeneca Plc Reaches Agreement With Trump Administration To Cut US Drug Prices - DirectorsTalk Interviews

02:08 AM
pulisher
01:21 AM

AstraZeneca Joins US President Trump's Drug-Cost Initiative, Secures Tariff Reprieve - MarketScreener

01:21 AM
pulisher
Oct 12, 2025

US FDA Commissioner’s Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions - insights.citeline.com

Oct 12, 2025
pulisher
Oct 12, 2025

President Trump announces deal with AstraZeneca on drug prices and tariffs - Taipei Times

Oct 12, 2025
pulisher
Oct 12, 2025

Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump - MarketScreener

Oct 12, 2025
pulisher
Oct 12, 2025

AstraZeneca PLC $AZN Shares Bought by Aberdeen Group plc - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

AstraZeneca PLC $AZN Stock Holdings Lowered by US Bancorp DE - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

AstraZeneca Signs US Drug Pricing Deal, Secures Three-year Delay to Tariffs - MarketScreener

Oct 12, 2025
pulisher
Oct 11, 2025

Target Identification and Validation In Drug Discovery - Oncodaily

Oct 11, 2025
pulisher
Oct 11, 2025

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts - ts2.tech

Oct 11, 2025
pulisher
Oct 11, 2025

Benson Investment Management Company Inc. Takes $4.44 Million Position in AstraZeneca PLC $AZN - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Mengis Capital Management Inc. Grows Stake in AstraZeneca PLC $AZN - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

AstraZeneca PLC $AZN Shares Acquired by Ramirez Asset Management Inc. - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

AstraZeneca PLC $AZN Stock Holdings Lowered by Blair William & Co. IL - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Callan Family Office LLC Has $3.90 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Trump announces deal with AstraZeneca to cut drug prices across US - Hindustan Times

Oct 11, 2025
pulisher
Oct 10, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca Strikes 'Most Favored Nation' Price Deal - Law360

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca (AZN) Reaches Agreement with White House to Lower Dr - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca Agrees To Lower Drug Prices For Medicaid Under Trump Administration Deal - Barchart.com

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca CEO says company granted three-year tariff exemption - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca : announces historic agreement with US Government to lower the cost of medicines for American patients - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Trump Announces AstraZeneca Drug Price Cuts for Tariff Reprieve - Yahoo Finance

Oct 10, 2025
pulisher
Oct 10, 2025

Trump says AstraZeneca to offer drugs to US at discounted prices - Reuters

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca (AZN) to Slash Drug Prices in New Deal - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Trump strikes drug-pricing deal with AstraZenecaMSNBC - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca’s stock is climbing after hours following a deal with the Trump White House - MarketWatch

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca set to announce drug price deal with Trump administrationBloomberg By Investing.com - Investing.com South Africa

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca follows Pfizer lead in making drug price deal with Trump - Seeking Alpha

Oct 10, 2025
pulisher
Oct 10, 2025

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income AmericansAstraZeneca (NASDAQ:AZN) - Benzinga

Oct 10, 2025
pulisher
Oct 10, 2025

AstraZeneca to strike landmark drug price deal with Trump administration - Business Standard

Oct 10, 2025
pulisher
Oct 10, 2025

Market Voices: Trump slams China on rare earths, AstraZeneca, UPS - Seeking Alpha

Oct 10, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):